Vascular allocation between liver and pancreas allografts: A retrospective single-center study

Table 1 Patients characteristic of pancreas-using group and non-pancreas-using group, n (%)/median (interquartile range)/mean ± SD

	Non-PUG (n = 68)	PUG (n = 34)	P value
Age (year)	55.34 ± 15.27	51.91 ± 10.77	0.814
Gender (male)	55 (80.9)	25 (73.5)	0.395
Height (cm)	171.22 ± 7.29	170.18 ± 6.96	0.49
Weight (kg)	69.10 ± 13.24	69.18 ± 17.46	0.978
Creatinine (μmol/L)	75.32 ± 39.33	69.14 ± 18.09	0.386
Albumin (g/L)	34.99 ± 6	35.33 ± 5.41	0.78
Model for end-stage liver disease score	15.94 ± 8.55	15.00 ± 6.70	0.576
Total bilirubin (μmol/L)	39.73 (18.20-83.43)	38.40 (16.26-73.3)	0.696
Alpha-fetoprotein (μg/L)	4.54 (2.13-13.48)	7.6 (2.32 ± 90.61)	0.255
Child-Pugh score
A	29 (42.6)	10 (29.4)	0.42
B	19 (27.9)	12 (35.3)
C	20 (29.4)	12 (35.3)
Primary disease			0.936
Benign end-stage disease	32 (47.1)	17 (50)
Liver malignant disease	27 (39.7)	14 (41.2)
Congenital, metabolic disease	2 (2.9)	1 (2.9)
Acute or subacute liver failure	7 (10.3)	2 (5.9)

PUG: Pancreas-using group.